Cargando…

Propofol Inhibits Proliferation and Augments the Anti-Tumor Effect of Doxorubicin and Paclitaxel Partly Through Promoting Ferroptosis in Triple-Negative Breast Cancer Cells

BACKGROUND: Triple-negative breast cancer (TNBC) is relatively common in women and is associated with a poor prognosis after surgery and adjuvant chemotherapy. Currently, the mechanism underlying the relationship between propofol and breast cancer is controversial and limited to cell apoptosis. More...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Chen, Liu, Pan, Pei, Lijian, Zhao, Mengyun, Huang, Yuguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996258/ https://www.ncbi.nlm.nih.gov/pubmed/35419287 http://dx.doi.org/10.3389/fonc.2022.837974

Ejemplares similares

Propofol Augments Paclitaxel-Induced Cervical Cancer Cell Ferroptosis In Vitro
por: Zhao, Meng-Yun, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer
por: Wu, Song, et al.
Publicado: (2022)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
por: Manouchehri, Jasmine M., et al.
Publicado: (2022)

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib
por: Song, Xiang, et al.
Publicado: (2020)

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
por: Zhang, Hao, et al.
Publicado: (2023)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
por: Clark, Curtis A., et al.
Publicado: (2021)

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
por: Wardhani, Bantari WK, et al.
Publicado: (2020)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Sun, Shanshan, et al.
Publicado: (2021)

Upregulation of the ferroptosis-related STEAP3 gene is a specific predictor of poor triple-negative breast cancer patient outcomes
por: Yuan, Lifang, et al.
Publicado: (2023)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Risk Stratification for Organ/Space Surgical Site Infection in Advanced Digestive System Cancer
por: Sun, Chen, et al.
Publicado: (2021)

POLD2 is activated by E2F1 to promote triple-negative breast cancer proliferation
por: Zhang, Zhen
Publicado: (2022)

Case Report: Postoperative Recurrence of Adrenal Epithelioid Angiosarcoma Achieved Complete Response by Combination Chemotherapy With Liposomal Doxorubicin and Paclitaxel
por: Wei, Hangping, et al.
Publicado: (2021)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Potential Influence of Anesthetic Interventions on Breast Cancer Early Recurrence According to Estrogen Receptor Expression: A Sub-Study of a Randomized Trial
por: Li, Mohan, et al.
Publicado: (2022)

CTSL, a prognostic marker of breast cancer, that promotes proliferation, migration, and invasion in cells in triple-negative breast cancer
por: Zhang, Lianmei, et al.
Publicado: (2023)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Incidence and risk factors for myocardial injury after laparoscopic adrenalectomy for pheochromocytoma: A retrospective cohort study
por: Lan, Ling, et al.
Publicado: (2022)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Prediction models for chronic postsurgical pain in patients with breast cancer based on machine learning approaches
por: Sun, Chen, et al.
Publicado: (2023)

Simvastatin induced ferroptosis for triple-negative breast cancer therapy
por: Yao, Xianxian, et al.
Publicado: (2021)

Ferroptosis: the emerging player in remodeling triple-negative breast cancer
por: Li, Jie, et al.
Publicado: (2023)

Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy
por: Sun, Yonghao, et al.
Publicado: (2022)

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
por: Ferreira, Arlindo R., et al.
Publicado: (2018)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
por: Gil-Gil, Miguel J., et al.
Publicado: (2021)

A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer
por: Qiu, Pengjun, et al.
Publicado: (2022)

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine
por: Yang, Fan, et al.
Publicado: (2023)

SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer
por: Zhang, Lei, et al.
Publicado: (2020)

ASMT Regulates Tumor Metastasis Through the Circadian Clock System in Triple-Negative Breast Cancer
por: Xie, FenFen, et al.
Publicado: (2020)

Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer
por: Wang, Xin-Hua, et al.
Publicado: (2022)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17g83a3i9jig00pndadngbh00s